HRTXHeron Therapeutics, Inc.

Company navigates mixed Q2 results with strong APONVIE growth, while withdrawing guidance due to CINVANTI patent challenges and exploring strategic alternatives.

Heron Therapeutics reported modest second-quarter revenue growth, but uncertainty around potential generic CINVANTI competition and a strategic alternatives process prompted the company to withdraw its full-year 2026 guidance. Key Investor TakeawaysHeron Therapeutics (NASDAQ:HRTX) reported Q2 2026 total net revenue of $37.

Heron Therapeutics (NASDAQ:HRTX) reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the comparable prior-year period, while management said sales of its key products came in below its internal expectations. Chief Executive Officer C

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50.00% and -11.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +14.29% and +1.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BioCryst (BCRX) delivered earnings and revenue surprises of +114.29% and +18.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.